Lead Academic Participating Site for the Development and Conduct of NCTN Trials

NCTN 试验开发和实施的主要学术参与网站

基本信息

批准号：
9221443
负责人：
ROBERT S. MANNEL
金额：
$ 20万
依托单位：
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-24 至 2016-04-19
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9221443
关键词：
Address Advisory Committees American College of Radiology Imaging Network American Indians Applications Grants Authorship Cancer Burden Cancer Center Cancer Therapy Evaluation Program Cancer and Leukemia Group B Clinical Clinical Research Clinical Trials Development Disease Eastern Cooperative Oncology Group Enrollment Ensure Extramural Activities Goals Grant Gynecologic Oncology Group Health Health Sciences Health Services Accessibility Image Information Dissemination Institution Lead Leadership Malignant Neoplasms Modality National Clinical Trials Network Nursing Research Oklahoma Outcome Patients Phase Play Population Public Health Publications Radiation Therapy Oncology Group Randomized Research Research Design Research Infrastructure Research Personnel Role Rural Site Social Workers Southwest Oncology Group Structure Therapeutic Trials Time Translational Research Underinsured Uninsured Universities Work base cancer care cancer clinical trial cancer health disparity cancer research center director clinical care data management design experience improved innovation knowledge base meetings multidisciplinary named group novel novel therapeutics operation organizational structure programs protocol development quality assurance standard of care statistical center therapy development working group

项目摘要

DESCRIPTION (provided by applicant): The Stephenson Cancer Center (SCC) at the University of Oklahoma Health Sciences Center (OUHSC) is applying to become a Lead Academic Site in the National Clinical Trials Network (NCTN). The SCC has been a leading accrual site for the NCTN, averaging 205 patients enrolled annually on CTEP trials over the past six years. Leading this effort are SCC Director Robert Mannel, MD (Contact PI) and Associate Director for Clinical Research Scott McMeekin, MD (PI). Both PIs have an outstanding record of scientific and administrative leadership. Along with the grant Investigators, they clearly demonstrate an ability and commitment to function as a coordinated research team and work effectively with components across the NCTN. The SCC is currently a primary institution for Gynecologic Oncology Group (GOG), Radiation Therapy Oncology Group (RTOG), and Alliance (previously CALGB). In addition, it registers patients on ECOG and SWOG trials through the CTSU mechanism and actively participates with ACRIN. The SCC has been a leader for the past decade in the design and conduct of CTEP trials that have defined the standard of care for numerous malignancies. Over the past six years the SCC enrolled 1,232 patients on CTEP therapeutic trials, including an all-time institutional high of 238 patients in 2012 (with projecte enrollment of 258 in 2013), making it a national leader in accrual for the NCTN. As a Lead Academic Site the SCC will continue to work with Network coordinating centers to be a leader in the design and conduct of NCTN trials for newly-developed therapies, including multi-modality treatments, combinations of novel agents, molecularity-based treatments, advanced imaging approaches, quality biospecimen acquisition and translational research. It will accomplish this goal within the context of providing high-quality cancer care and access to NCTN clinical trials for Oklahomans, especially for the state's special populations that experience significantly high rates of cancer health disparities. As the state's only academic cancer center, the SCC plays a crucial role in providing all Oklahomans access to NCTN clinical trials, definitively evaluating novel therapies, raising the standard of care and easing the burden of cancer for the region.

描述（由申请人提供）：俄克拉荷马大学健康科学中心（OUHSC）的斯蒂芬森癌症中心（SCC）申请成为国家临床试验网络（NCTN）的主要学术地点。 SCC一直是NCTN领先的应计部位，在过去六年中，每年有205名患者参加CTEP试验。 SCC主任Robert Mannel，医学博士（联系PI）和临床研究副总监Scott McMeekin，医学博士（PI）（PI）。这两个PI都具有科学和行政领导的出色记录。与赠款调查人员一起，他们清楚地表明了作为协调研究团队的能力和承诺，并有效地与NCTN的组件有效地工作。 SCC目前是妇科肿瘤学组（GOG），放射治疗肿瘤学组（RTOG）和联盟（以前的CALGB）的主要机构。此外，它通过CTSU机制将患者注册在ECOG和SWOG试验中，并积极参与ACRIN。在过去的十年中，SCC一直是CTEP试验的设计和行为的领导者，这些试验定义了许多恶性肿瘤的护理标准。在过去的六年中，SCC招募了1,232例CTEP治疗试验患者，包括2012年有史以来238名患者的历史最高率（2013年Projecte入学率为258例），使其成为NCTN的全国领导者。作为主要学术网站，SCC将继续与网络协调中心合作，成为新开发疗法的NCTN试验的领导者，包括多模式疗法，新型药物的组合，基于分子的治疗方法，高级成像方法，优质的生物生物生物生物习得和翻译研究。它将在为俄克拉荷马人提供高质量的癌症护理并获得NCTN临床试验的背景下实现这一目标，尤其是对于该州的特殊人群而言，经历了癌症健康差异的高度。作为该州唯一的学术癌症中心，SCC在为所有俄克拉荷马人提供NCTN临床试验方面起着至关重要的作用，确定评估了新型疗法，提高了护理标准并减轻了该地区的癌症负担。